• Genomics
  • Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy," Pharmacogenetics and Genomics , vol. 17, no. 9, pp. 755-764, 2007. (hindawi.com)
  • adults
  • See 'Overview of medical care in adults with diabetes mellitus', section on 'Dyslipidemia' . (uptodate.com)
  • Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group," Clinical Infectious Diseases , vol. 37, no. 5, pp. 613-627, 2003. (hindawi.com)
  • clinical
  • Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. (springer.com)
  • Circulation
  • Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study," Circulation , vol. 2, no. 6, pp. 621-628, 2009. (hindawi.com)
  • Genetic
  • citation needed] Physicians and basic researchers classify dyslipidemias in two distinct ways: Presentation in the body (including the specific type of lipid that is increased) Underlying cause for the condition (genetic, or secondary to another condition). (wikipedia.org)
  • Genes
  • Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia," American Journal of Human Genetics , vol. 82, no. 1, pp. 139-149, 2008. (hindawi.com)
  • diabetes
  • The most common conditions that were felt to be contributing to dyslipidemia were excessive alcohol intake (10 percent) and uncontrolled diabetes mellitus (8 percent). (uptodate.com)
  • risk
  • This article provides a framework for diagnosing and managing dyslipidaemia, with the aim of reducing patients' CVD risk. (bmj.com)
  • patients
  • Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. (springer.com)
  • However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. (springer.com)
  • Eighty-one percent of all patients had dyslipidemia (DL) and a majority of the patients with abdominal measures below the recommended cut-off levels had DL. (diva-portal.org)